Chronic hepatitis B virus (HBV)-infected patients may exhibit liver fibrosis and other pathological changes despite normal alanine aminotransferase (ALT). This study aimed to assess the efficacy and ...

Long-term mortality outcomes were similar in patients with CHB receiving treatment with entecavir or tenofovir. Patients with chronic hepatitis B (CHB) treated with entecavir vs tenofovir disoproxil ...

TMF is comparable to TDF in terms of CHB treatment effectiveness, with better renal safety and no impact on lipid levels. In TE patients, transitioning to TMF therapy does not affect antiviral ...

Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled ...

Tenofovir amibufenamide treatment demonstrates significant efficacy in chronic HBV-infected patients with normal ALT levels and shows a favorable safety profile regarding bone, renal, and lipid ...

Please provide your email address to receive an email when new articles are posted on . High rates of sustained virologic response were achieved after 12 weeks of sofosbuvir/velpatasvir plus tenofovir ...

VIENNA -- Tenofovir alafenamide (TAF; Biktarvy) continued to be highly effective for chronic hepatitis B virus (HBV) infection for up to 8 years, according to an analysis of long-term data. Over this ...

MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has ...